METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to stall spread of prostate cancer
Disease control CompletedThis large Phase 3 trial tested whether adding the immunotherapy pembrolizumab (Keytruda) to standard hormone therapy (enzalutamide plus ADT) could improve outcomes for men with metastatic hormone-sensitive prostate cancer. Over 1,200 participants were enrolled. The study was unb…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising drug combo slows advanced prostate cancer in major trial
Disease control CompletedThis study tested whether adding darolutamide to standard hormone therapy helps men with prostate cancer that has spread to other parts of the body. 669 men participated. The goal was to see if the combination delays cancer growth or death. Results showed improvement in progressi…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Chemo combo boosts survival in advanced prostate cancer
Disease control CompletedThis large phase 3 trial tested whether adding the chemotherapy drug docetaxel to standard hormone therapy helps men with metastatic prostate cancer live longer. 790 men participated. The results showed that the combination improved overall survival compared to hormone therapy al…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise for advanced prostate cancer
Disease control CompletedThis Phase 3 study tested whether adding darolutamide to standard hormone therapy and chemotherapy helps men with metastatic hormone-sensitive prostate cancer live longer. Over 1,300 participants received either darolutamide or a placebo, along with standard treatments. The main …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Triple-Drug cocktail shows promise in early prostate cancer trial
Disease control CompletedThis early-phase trial tested a combination of three drugs—cabozantinib, abiraterone, and nivolumab—in 18 men with metastatic hormone-sensitive prostate cancer that had not yet been treated. The main goal was to find a safe dose and check for serious side effects. Researchers als…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo slows prostate cancer spread in large trial
Disease control CompletedThis large phase 3 trial tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps men with metastatic hormone-sensitive prostate cancer. Over 1,100 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how lo…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Prostate cancer drug combo trial halted early – no benefit seen
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New model predicts prostate cancer treatment response using PET scans
Knowledge-focused CompletedThis study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The goal was to help doctors better understand which p…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC